Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Net Income (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Net Income for 15 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income rose 74.31% to -$1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$67.0 million, a 378.88% decrease, with the full-year FY2024 number at -$12.1 million, down 279.51% from a year prior.
  • Net Income was -$1.2 million for Q3 2025 at Harvard Bioscience, up from -$2.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $2.4 million in Q2 2022 to a low of -$50.3 million in Q1 2025.
  • A 5-year average of -$4.7 million and a median of -$1.6 million in 2022 define the central range for Net Income.
  • Biggest YoY gain for Net Income was 693.9% in 2022; the steepest drop was 1902.94% in 2022.
  • Harvard Bioscience's Net Income stood at $590000.0 in 2021, then tumbled by 376.1% to -$1.6 million in 2022, then fell by 0.31% to -$1.6 million in 2023, then crashed by 706.92% to -$13.2 million in 2024, then skyrocketed by 90.66% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Net Income are -$1.2 million (Q3 2025), -$2.3 million (Q2 2025), and -$50.3 million (Q1 2025).